全文获取类型
收费全文 | 114224篇 |
免费 | 8131篇 |
国内免费 | 3856篇 |
专业分类
耳鼻咽喉 | 601篇 |
儿科学 | 1792篇 |
妇产科学 | 1077篇 |
基础医学 | 14609篇 |
口腔科学 | 1608篇 |
临床医学 | 9863篇 |
内科学 | 20318篇 |
皮肤病学 | 1040篇 |
神经病学 | 12097篇 |
特种医学 | 3043篇 |
外国民族医学 | 4篇 |
外科学 | 8468篇 |
综合类 | 15783篇 |
现状与发展 | 11篇 |
预防医学 | 12582篇 |
眼科学 | 1586篇 |
药学 | 13579篇 |
102篇 | |
中国医学 | 3827篇 |
肿瘤学 | 4221篇 |
出版年
2024年 | 285篇 |
2023年 | 1507篇 |
2022年 | 2778篇 |
2021年 | 3761篇 |
2020年 | 3599篇 |
2019年 | 3719篇 |
2018年 | 3651篇 |
2017年 | 3469篇 |
2016年 | 3664篇 |
2015年 | 3816篇 |
2014年 | 7049篇 |
2013年 | 7879篇 |
2012年 | 6688篇 |
2011年 | 7332篇 |
2010年 | 5685篇 |
2009年 | 5472篇 |
2008年 | 5590篇 |
2007年 | 5600篇 |
2006年 | 4990篇 |
2005年 | 4321篇 |
2004年 | 3697篇 |
2003年 | 3331篇 |
2002年 | 2709篇 |
2001年 | 2381篇 |
2000年 | 2027篇 |
1999年 | 1773篇 |
1998年 | 1627篇 |
1997年 | 1650篇 |
1996年 | 1318篇 |
1995年 | 1277篇 |
1994年 | 1182篇 |
1993年 | 963篇 |
1992年 | 883篇 |
1991年 | 797篇 |
1990年 | 647篇 |
1989年 | 574篇 |
1988年 | 553篇 |
1987年 | 508篇 |
1986年 | 472篇 |
1985年 | 936篇 |
1984年 | 976篇 |
1983年 | 704篇 |
1982年 | 689篇 |
1981年 | 655篇 |
1980年 | 591篇 |
1979年 | 479篇 |
1978年 | 417篇 |
1977年 | 329篇 |
1976年 | 343篇 |
1975年 | 290篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
61.
目的 初步探讨应用艾尔巴韦/格拉瑞韦治疗慢性丙型肝炎(CHC)患者的疗效。方法 2017年3月~2018年3月仙桃市第一人民医院感染病科收治的CHC患者82例,被随机分为对照组41例和观察组41例,分别给予聚乙二醇干扰素-α联合利巴韦林治疗和艾尔巴韦/格拉瑞韦治疗,两组均连续治疗24周。采用RT- PCR法检测血清 HCV RNA,采用全基因序列测定法行病毒基因分型。比较两组早期病毒学应答(EVR)、治疗结束时病毒学应答(ETVR)和持续病毒学应答(SVR)。结果 在治疗结束时,观察组血清丙氨酸氨基转移酶(ALT)水平为(47.9±19.7)U/L,显著低于对照组【(63.5±21.2)U/L,P<0.05】,天冬氨酸氨基转移酶(AST)水平为(55.5±22.3)U/L,显著低于对照组【(81.3±25.8)U/L,P<0.05】;观察组EVR、ETVR和SVR分别为48.8%、63.4%和70.7%,与对照组的41.5%、53.7%和65.8%比,无统计学差异(P>0.05);18例观察组非HCV Ⅰ型感染者EVR、ETVR和SVR分别为88.9%、94.4%和88.9%,显著高于同组23例HCV Ⅰ型感染者(分别为52.2%、60.9%和52.2%, P<0.05),而与对照组15例非HCV Ⅰ型感染者比,无统计学差异(分别为86.7%、93.3%和73.3%, P>0.05);观察组SVR12为87.8%(36/41),显著高于对照组的73.2%(30/41,P<0.05)。结论 应用直接抗病毒(DAA)药物艾尔巴韦/格拉瑞韦治疗CHC患者近期疗效达到,但远期疗效似优于标准治疗方案, 值得临床进一步验证。 相似文献
62.
63.
64.
65.
66.
67.
Hepatitis C is a major public health problem worldwide. This disease is caused by the hepatitis C virus, which is characterised by its genetic diversity. The infection is usually asymptomatic. However, between 60% and 80% of HCV-infected individuals will progress to chronic hepatitis, 20% to liver cirrhosis in the medium-to long-term and, each year, between 1% and 4% of these patients with cirrhosis will develop hepatocellular carcinoma (HCC). A Spanish consensus document has recently been drafted to diagnose hepatitis C in a single step, consisting of active investigation (antibodies and viremia) in a single sample, which according to the experts, would reduce the time to access treatment and avoid tracking losses. To definitively change the hepatitis C treatment paradigm, direct-acting antiviral drugs (DAAs) have been approved, whose development has been based on achieving cure rates close to 100% regardless of the genotype of the virus, ie, pangenotypes, with good tolerance and bioavailability. These drugs have constituted a real therapeutic revolution. Supplement information: This article is part of a supplement entitled «SEIMC External Quality Control Programme. Year 2016», which is sponsored by Roche, Vircell Microbiologists, Abbott Molecular and Francisco Soria Melguizo, S.A.© 2019 Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosasy Microbiología Clínica. All rights reserved. 相似文献
68.
Lesley A. Inker Morgan E. Grams Andrew S. Levey Josef Coresh Massimo Cirillo John F. Collins Ron T. Gansevoort Orlando M. Gutierrez Takayuki Hamano Gunnar H. Heine Shizukiyo Ishikawa Sun Ha Jee Florian Kronenberg Martin J. Landray Katsuyuki Miura Girish N. Nadkarni Carmen A. Peralta Dietrich Rothenbacher Mark Woodward 《American journal of kidney diseases》2019,73(2):206-217
69.
《Journal of pharmaceutical sciences》2019,108(10):3425-3433
This study aimed at evaluating how encapsulation in a regular nanocarrier (NC) (providing extended circulation time) or in a brain-targeting NC (providing prolonged circulation time and increased brain uptake) may influence the therapeutic index compared with the unformulated drug and to explore the key parameters affecting therapeutic performance using a model-based approach. Pharmacokinetic (PK) models were built with chosen PK parameters. For a scenario where central effect depends on area under the unbound brain concentration curve and peripheral toxicity relates to peak unbound plasma concentration, dose-effect and drug-side effect curves were constructed, and the therapeutic index was evaluated. Regular NC improved the therapeutic index compared with the unformulated drug due to reduced peripheral toxicity, while brain-targeting NC enhanced the therapeutic index by lowering peripheral toxicity and increasing central effect. Decreasing drug release rate or systemic clearance of NC with drug still encapsulated could increase the therapeutic index. Also, a drug with shorter half-life would therapeutically benefit more from a NC encapsulation. This work provides insights into how a NC for brain delivery should be optimized to maximize the therapeutic performance and is helpful to predict if and to what extent a drug with certain PK properties would obtain therapeutic benefit from nanoencapsulation. 相似文献
70.
Renal Denervation for Treatment of Cardiac Arrhythmias: State of the Art and Future Directions
下载免费PDF全文
![点击此处可从《Journal of cardiovascular electrophysiology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
JEDRZEJ KOSIUK M.D. SEBASTIAN HILBERT M.D. EVGENY POKUSHALOV M.D. GERHARD HINDRICKS M.D. Ph.D. JONATHAN S. STEINBERG M.D. ANDREAS BOLLMANN M.D. Ph.D. 《Journal of cardiovascular electrophysiology》2015,26(2):233-238
Renal Denervation for Treatment of Cardiac Arrhythmias . It has now been more than a quarter of a century since modulation of the sympathetic nervous system was proposed for the treatment of cardiac arrhythmias of different origins. But it has also been some time since some of the early surgical attempts have been abandoned. With the development of ablation techniques, however, new approaches and targets have been recently introduced that have revolutionized our way of thinking about sympathetic modulation. Renal nerve ablation technology is now being successfully used for the treatment of resistant hypertension, but the indication spectrum might broaden and new therapeutic options might arise in the near future. This review focuses on the possible impact of renal sympathetic system modulation on cardiac arrhythmias, the current evidence supporting this approach, and the ongoing trials of this method in electrophysiological laboratories. We will discuss the potential roles that sympathetic modulation may play in the future. 相似文献